Maysa Abu-Khalaf MBBS, MD
Associate Professor of Medicine (Medical Oncology) and of Obstetrics, Gynecology, and Reproductive Sciences
Breast Cancer: Early and advanced stages, hormone receptor positive breast cancers, triple negative breast cancers, HER-2 positive breast cancers, adjuvant (postoperative) treatment, neoadjuvant (preoperative) treatment, metastatic breast cancer treatment, clinical trials.
Gynecologic Cancers: Advanced/recurrent ovarian and endometrial cancers, clinical trials.
maysa_abu-khalaf faculty-clinics false true false Clinical Trials
Conditions Study Title Cancer, Breast - Female, and Breast - Male Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (S1207) Breast - Female and Breast - Male A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study) Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and Stomach A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications Breast - Female A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer Breast - Female S1222: FULVESTRANT ALONE VERSUS FULVESTRANT AND EVEROLIMUS VERSUS FULVESTRANT, EVEROLIMUS AND ANASTROZOLE: A PHASE III RANDOMIZED PLACEBO-CONTROLLED TRIAL IN POSTMENOPAUSAL PATIENTS WITH HORMONE-RECEPTOR-POSITIVE STAGE IV BREAST CANCER